Bausch Health Q2 Revenue Hits $2.85B, Raises Full-Year Guidance
BHC is trading near its 52-week low of $4.33 (12% above the low).
Summary
Bausch Health reported Q2 2026 revenue of $2.85 billion, up 13%, with GAAP EPS of $0.68 and Adjusted EPS of $1.26. The company raised full-year guidance across key metrics.
Key Events · Earnings and Guidance · BHC
-
Q2 Revenue Surges 13% to $2.85B
Consolidated revenue reached $2.85 billion, up 13% reported and 11% organic, led by Salix segment growth of 21%.
-
GAAP EPS of $0.68, Adjusted EPS of $1.26
GAAP net income attributable to Bausch Health was $258 million, or $0.68 per diluted share, compared to $0.40 a year ago. Adjusted EPS rose 40% to $1.26.
-
Adjusted EBITDA Climbs 28% to $1.075B
Consolidated Adjusted EBITDA attributable to Bausch Health was $1,075 million, up from $842 million in Q2 2025.
-
Full-Year 2026 Guidance Raised
The company raised its full-year outlook for Revenue, Adjusted EBITDA, and Adjusted Cash Flows from Operations, reflecting confidence in continued growth.
Analysis · BHC · Life Sciences
A standout second quarter saw consolidated revenue reach $2.85 billion, up 13% on a reported basis and 11% organically, fueled by a 21% surge in the Salix segment. GAAP net income attributable to Bausch Health came in at $258 million, or $0.68 per diluted share, compared with $0.40 a year ago. Adjusted EBITDA jumped 28% to $1,075 million. Reflecting confidence in sustained momentum, the company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted Cash Flows from Operations. This marks the thirteenth consecutive quarter of year-over-year growth for Bausch Health excluding Bausch + Lomb, and the highest revenue and Adjusted EBITDA growth rates in three years.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHC was trading at $4.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.33 to $8.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.